All In Biotech

Drug Trial Radar · NCT04234906

Prevention of Post-Operative Cardiac Arrhythmias

Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias

Last checked: Nov 19, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 870 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

870

Planned (sponsor's estimate)

Start

Jan 2023

Primary completion

Apr 2023

Study completion Aug 2023

Sponsor

Lead sponsor
Jeffrey MoakAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Aim 1: Primary Prevention of Post-operative Cardiac Arrhythmias 1. To evaluate the efficacy of dexmedetomidine vs. the combination of Magnesium Sulfate and dexmedetomidine for the prevention of post-operative cardiac arrhythmias in children and young adults undergoing open heart surgical repair for congenital or acquired heart disease using cardiopulmonary bypass. Dexmedetomidine is currently being administered to almost all patients after coming off cardiopulmonary bypass and in the CICU. For this aim, the investigator will be comparing dexmedetomidine administered alone or in combination with Magnesium Sulfate. 2. To evaluate medication safety based on the frequency of Serious Adverse Events (SAEs) and Adverse Events (AEs) Aim 2: Secondary treatment of those Patients that develop a clinically significant arrhythmia despite having received either Dexmedetomidine alone or Magnesium Sulfate with Dexmedetomidine at the time of cardiac surgery 1. To evaluate the efficacy of intravenous (IV) Amiodarone vs. IV Procainamide for the control of postoperative cardiac arrhythmias developing after the failure of Stage 1, Preventative Trial. IV amiodarone and IV procainamide are standardly used treatment agents for the treatment of postoperative cardiac arrhythmias in this setting. The investigator will be assessing the comparative effectiveness of these agents in controlling post-operative cardiac arrhythmias. 2. To evaluate antiarrhythmic medication safety based on the frequency of SAEs and AEs

Conditions

  • Cardiac; Dysrhythmia, Postoperative
  • Congenital Heart Surgery

Interventions

  • DexmedetomidineDrug

    Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period

  • Magnesium SulfateDrug

    Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day

  • AmiodaroneDrug

    I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours

  • ProcainamideDrug

    IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Post-Operative Cardiac ArrhythmiasTime frame: 3 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.